martes, 2 de octubre de 2012

National Coverage Analysis (NCA) Tracking Sheet for Aprepitant for Chemotherapy-Induced Emesis (CAG-00248R)

full-text ►
National Coverage Analysis (NCA) Tracking Sheet for Aprepitant for Chemotherapy-Induced Emesis (CAG-00248R)

Centers for Medicare & Medicaid Services 

Aprepitant (Emend®) is an orally administered neurokinin-1 antagonist that is proposed to function in combination with other oral anti-emetics specifically for patients receiving highly or moderately emetogenic chemotherapy.
In April 2005, the Centers for Medicare and Medicaid Services (CMS) published a National Coverage Decision (NCD) for Aprepitant for Chemotherapy-Induced Emesis (110.18). At that time, CMS determined that the evidence was adequate to conclude that the oral anti-emetic three drug combination of aprepitant (Emend®), a 5-HT3 antagonist, and dexamethasone is reasonable and necessary for patients who are receiving one or more of the following highly emetogenic anti-cancer chemotherapeutic agents:
- Carmustine,- Cisplatin,- Cyclophosphamide,
- Dacarbazine,- Mechlorethamine,- Streptozocin,
- Doxorubicin,- Epirubicin,- Lomustine
CMS is reconsidering NCD 110.18 to review the evidence on the use of oral aprepitant (Emend®) in combination with dexamethasone and a 5-HT3 antagonist in patients receiving moderately emetogenic anti-cancer chemotherapeutic agents
National Coverage Analysis (NCA) Tracking Sheet for Aprepitant for Chemotherapy-Induced Emesis (CAG-00248R)

No hay comentarios: